Thaís Sant'Anna1, Leila Donária1, Nidia A Hernandes1, Karina C Furlanetto1, Décio S Barbosa2, Rik Gosselink3, Fabio Pitta4. 1. Laboratory of Research in Respiratory Physiotherapy, Department of Physiotherapy, State University of Londrina, Av. Robert Koch, 60 - Vila Operária, Londrina, Parana, 86038-350, Brazil. 2. Health Sciences Graduate Program, Health Sciences Center, State University of Londrina, Av. Robert Koch, 60 - Vila Operária, Londrina, Parana, 86038-350, Brazil. 3. Respiratory Division and Pulmonary Rehabilitation, University Hospitals, Katholieke Universiteit Leuven, Herestraat 49, 3000, Leuven, Belgium. 4. Laboratory of Research in Respiratory Physiotherapy, Department of Physiotherapy, State University of Londrina, Av. Robert Koch, 60 - Vila Operária, Londrina, Parana, 86038-350, Brazil. fabiopitta@uol.com.br.
Abstract
PURPOSE: To analyze the relationship between oxygen desaturation episodes during a laboratory-based ADL protocol and in real-life routine in patients with stable chronic obstructive pulmonary disease (COPD). METHODS: Twenty patients with stable COPD (12 men, 70 ± 7 years, FEV1% 54 ± 15 predicted) with no indication for long-term oxygen therapy (LTOT) were submitted to assessments including ADL performance by the Londrina ADL Protocol (LAP) and level of physical activity in daily life, both while submitted to simultaneous activity and pulse oximeter monitoring. RESULTS: Episodes of desaturation ≥ 4% (ED ≥ 4%) during the LAP were correlated both with ED ≥ 4% in daily life (r = 0.45) and number of episodes of SpO2 under 88% (ED < 88%) in daily life (r = 0.59). ED < 88% during the LAP was also correlated with ED < 88% in daily life (r = 0.51), explaining 43% of its variance. CONCLUSION: In stable patients with COPD and no indication of LTOT, episodes of desaturation during a lab-based ADL protocol are moderately related to episodes of desaturation in daily (real) life, especially those episodes under 88%.
PURPOSE: To analyze the relationship between oxygen desaturation episodes during a laboratory-based ADL protocol and in real-life routine in patients with stable chronic obstructive pulmonary disease (COPD). METHODS: Twenty patients with stable COPD (12 men, 70 ± 7 years, FEV1% 54 ± 15 predicted) with no indication for long-term oxygen therapy (LTOT) were submitted to assessments including ADL performance by the Londrina ADL Protocol (LAP) and level of physical activity in daily life, both while submitted to simultaneous activity and pulse oximeter monitoring. RESULTS: Episodes of desaturation ≥ 4% (ED ≥ 4%) during the LAP were correlated both with ED ≥ 4% in daily life (r = 0.45) and number of episodes of SpO2 under 88% (ED < 88%) in daily life (r = 0.59). ED < 88% during the LAP was also correlated with ED < 88% in daily life (r = 0.51), explaining 43% of its variance. CONCLUSION: In stable patients with COPD and no indication of LTOT, episodes of desaturation during a lab-based ADL protocol are moderately related to episodes of desaturation in daily (real) life, especially those episodes under 88%.
Entities:
Keywords:
Activities of daily living; Chronic obstructive pulmonary disease; Motor activity; Pulse oximetry
Authors: Henrik Watz; Fabio Pitta; Carolyn L Rochester; Judith Garcia-Aymerich; Richard ZuWallack; Thierry Troosters; Anouk W Vaes; Milo A Puhan; Melissa Jehn; Michael I Polkey; Ioannis Vogiatzis; Enrico M Clini; Michael Toth; Elena Gimeno-Santos; Benjamin Waschki; Cristobal Esteban; Maurice Hayot; Richard Casaburi; Janos Porszasz; Edward McAuley; Sally J Singh; Daniel Langer; Emiel F M Wouters; Helgo Magnussen; Martijn A Spruit Journal: Eur Respir J Date: 2014-10-30 Impact factor: 16.671
Authors: Fabio Pitta; Thierry Troosters; Martijn A Spruit; Vanessa S Probst; Marc Decramer; Rik Gosselink Journal: Am J Respir Crit Care Med Date: 2005-01-21 Impact factor: 21.405
Authors: Fábio Pitta; Marie-Kathrin Breyer; Nídia A Hernandes; Denílson Teixeira; Thaís J P Sant'Anna; Andréa D Fontana; Vanessa S Probst; Antonio F Brunetto; Martijn A Spruit; Emiel F M Wouters; Otto C Burghuber; Sylvia Hartl Journal: Respir Med Date: 2008-11-09 Impact factor: 3.415